Mkango Releases Financial Statements and Management’s Discussion and Analysis for the Period Ending December 31, 2019

Mkango Releases Financial Statements and Management’s Discussion and Analysis for the Period Ending December 31, 2019

LONDON and VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) — Mkango Resources Ltd. (AIM/TSX-V: MKA) (the “Company” or “Mkango“) is pleased to announce that it has released the Financial Statements and Management’s Discussion and Analysis for the period ending December 31, 2019. The reports will be available under the Company’s profile on SEDAR (www.sedar.com) and on the Company’s website (http://www.mkango.ca/s/financials.asp).
For further information on Mkango, please contact:
Mkango Resources Limited
William Dawes                               Alexander Lemon
Chief Executive Officer                  President
will@mkango.ca                            alex@mkango.ca
Canada: +1 403 444 5979
www.mkango.ca
@MkangoResources
Blytheweigh
Financial Public Relations
Tim Blythe, Camilla Horsfall
UK: +44 207 138 3204
SP Angel Corporate Finance LLP
Nominated Adviser and Joint Broker
Jeff Keating, Caroline Rowe
UK: +44 20 3470 0470
Alternative Resource Capital
Joint Broker
Alex Wood, Rob Collins
UK: +44 20 7186 9004; +44 20 7186 9001
The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.This press release does not constitute an offer to sell or a solicitation of an offer to buy any equity or other securities of the Company in the United States. The securities of the Company will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold within the United States to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act.
CBJ Newsmakers

Recommended
Fura to Rely on Extension of Time to File Financial StatementsWPD Pharmaceutical’s Annamycin Drug Approved for Accelerated European Clinical Trial